Hyundai Bioscience Co. Ltd - Asset Resilience Ratio
Hyundai Bioscience Co. Ltd (048410) has an Asset Resilience Ratio of 22.98% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 048410 net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2002–2025)
This chart shows how Hyundai Bioscience Co. Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of Hyundai Bioscience Co. Ltd.
Liquid Assets Composition Over Time
This chart breaks down Hyundai Bioscience Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Hyundai Bioscience Co. Ltd (048410) investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩29.67 Billion | 22.98% |
| Total Liquid Assets | ₩29.67 Billion | 22.98% |
Asset Resilience Insights
- Good Liquidity Position: Hyundai Bioscience Co. Ltd maintains a healthy 22.98% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Hyundai Bioscience Co. Ltd Industry Peers by Asset Resilience Ratio
Compare Hyundai Bioscience Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Hyundai Bioscience Co. Ltd (2002–2025)
The table below shows the annual Asset Resilience Ratio data for Hyundai Bioscience Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 13.57% | ₩17.74 Billion ≈ $12.02 Million |
₩130.74 Billion ≈ $88.60 Million |
-5.37pp |
| 2023-12-31 | 18.94% | ₩10.00 Billion ≈ $6.78 Million |
₩52.79 Billion ≈ $35.78 Million |
-8.88pp |
| 2022-12-31 | 27.82% | ₩18.73 Billion ≈ $12.69 Million |
₩67.33 Billion ≈ $45.63 Million |
+0.26pp |
| 2021-12-31 | 27.57% | ₩22.20 Billion ≈ $15.04 Million |
₩80.53 Billion ≈ $54.57 Million |
+6.76pp |
| 2020-12-31 | 20.81% | ₩19.21 Billion ≈ $13.02 Million |
₩92.31 Billion ≈ $62.56 Million |
+9.65pp |
| 2019-12-31 | 11.16% | ₩7.06 Billion ≈ $4.78 Million |
₩63.24 Billion ≈ $42.85 Million |
+5.30pp |
| 2018-12-31 | 5.85% | ₩3.16 Billion ≈ $2.14 Million |
₩54.01 Billion ≈ $36.60 Million |
-9.32pp |
| 2017-12-31 | 15.17% | ₩7.51 Billion ≈ $5.09 Million |
₩49.50 Billion ≈ $33.54 Million |
-8.69pp |
| 2016-12-31 | 23.86% | ₩12.74 Billion ≈ $8.63 Million |
₩53.38 Billion ≈ $36.18 Million |
+21.76pp |
| 2015-12-31 | 2.10% | ₩910.00 Million ≈ $616.69K |
₩43.41 Billion ≈ $29.42 Million |
-0.68pp |
| 2014-12-31 | 2.77% | ₩910.00 Million ≈ $616.69K |
₩32.81 Billion ≈ $22.23 Million |
+2.32pp |
| 2013-12-31 | 0.45% | ₩140.09 Million ≈ $94.94K |
₩30.84 Billion ≈ $20.90 Million |
+0.45pp |
| 2012-12-31 | 0.00% | ₩66.00K ≈ $44.73 |
₩32.06 Billion ≈ $21.73 Million |
-5.43pp |
| 2011-12-31 | 5.43% | ₩1.65 Billion ≈ $1.12 Million |
₩30.47 Billion ≈ $20.65 Million |
+5.11pp |
| 2010-12-31 | 0.32% | ₩154.50 Million ≈ $104.71K |
₩48.45 Billion ≈ $32.83 Million |
-4.12pp |
| 2009-12-31 | 4.43% | ₩2.71 Billion ≈ $1.84 Million |
₩61.19 Billion ≈ $41.46 Million |
+0.43pp |
| 2008-12-31 | 4.01% | ₩3.51 Billion ≈ $2.38 Million |
₩87.53 Billion ≈ $59.31 Million |
-13.64pp |
| 2007-12-31 | 17.65% | ₩18.21 Billion ≈ $12.34 Million |
₩103.16 Billion ≈ $69.91 Million |
+15.06pp |
| 2006-12-31 | 2.58% | ₩2.73 Billion ≈ $1.85 Million |
₩105.52 Billion ≈ $71.51 Million |
-15.58pp |
| 2005-12-31 | 18.16% | ₩41.93 Billion ≈ $28.41 Million |
₩230.83 Billion ≈ $156.43 Million |
+3.53pp |
| 2004-12-31 | 14.64% | ₩32.91 Billion ≈ $22.30 Million |
₩224.80 Billion ≈ $152.34 Million |
+1.80pp |
| 2003-12-31 | 12.84% | ₩31.14 Billion ≈ $21.10 Million |
₩242.55 Billion ≈ $164.37 Million |
-4.91pp |
| 2002-12-31 | 17.74% | ₩35.59 Billion ≈ $24.12 Million |
₩200.60 Billion ≈ $135.94 Million |
-- |
About Hyundai Bioscience Co. Ltd
Hyundai Bioscience Co., Ltd. operates as a biotechnology company. The company provides Vitabrid C12, a vitamin C product that delivers active vitamin C into the skin. It develops Polytaxel, a drug for pancreatic cancer and solid tumors; and CP-COV03 drug for Covid 19. The company was founded in 2000 and is based in Seoul, South Korea.